Pharmacokinetics and Tissue Distribution of 13 C-Labeled Succinic Acid in Mice.
Yonghwan JungJin Sook SongSunjoo AhnPublished in: Nutrients (2022)
Succinic acid is widely used as a food additive, and its effects on sepsis, cancer, ataxia, and obesity were recently reported. Dietary drug exposure studies have been conducted to evaluate the in vivo efficacy of succinic acid, but limited pharmacokinetic information is available. Therefore, this study evaluated the pharmacokinetic profiles and tissue distribution of succinic acid following a single intravenous or oral dose. A surrogate analyte, succinic acid- 13 C 4 ( 13 C 4 SA), was administrated to distinguish endogenous and exogenous succinic acid. The concentration of 13 C 4 SA was determined by a validated analytical method using mass spectrometry. After a 10 mg/kg intravenous dose, non-compartmental pharmacokinetic analysis in plasma illustrated that the clearance, volume of distribution, and terminal half-life of 13 C 4 SA were 4574.5 mL/h/kg, 520.8 mL/kg, and 0.56 h, respectively. Oral 13 C 4 SA was absorbed and distributed quickly (bioavailability, 1.5%) at a dose of 100 mg/kg. In addition, 13 C 4 SA exposure was the highest in the liver, followed by brown adipose tissue, white adipose tissue, and the kidneys. This is the first report on the pharmacokinetics of succinic acid after a single dose in mice, and these results could provide a foundation for selecting dosing regimens for efficacy studies.
Keyphrases
- adipose tissue
- mass spectrometry
- insulin resistance
- high fat diet induced
- emergency department
- type diabetes
- high dose
- squamous cell carcinoma
- intensive care unit
- climate change
- healthcare
- skeletal muscle
- high fat diet
- risk assessment
- liquid chromatography
- physical activity
- early onset
- pet ct
- health information
- solid phase extraction